SRNE - Sorrento granted FDA OK for IND to conduct trial of oncolytic virus candidate

The FDA has authorized Sorrento Therapeutics' (NASDAQ:SRNE) IND application for a phase 1b trial of STI-1386 (Seprehvec) for oncolytic virus in patients with relapsed or refractor solid tumors. "Seprehvec allows for locoregional immune stimulation at the tumor site while potentially minimizing the undesired effects that may accompany systemic immune stimulation," said Sorrento CMO Mike Royal. The company says trials on Seprehvec will initially focus on sarcomas, pancreatic carcinomas, and hepatic metastases before expanding to other solid tumors. Read about recent trial results for SP-102, a corticosteroid for sciatica.

For further details see:

Sorrento granted FDA OK for IND to conduct trial of oncolytic virus candidate